Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Aug. 13, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that its V.P.,\n Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster\n presentation on preclinical results for the Company's novel orally\n active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the 244th National Meeting of the American Chemistry Society which will be held\n August 19-23, 2012, in Philadelphia.\n\n\n\n\n\nPoster #46:\n\n\n \n\n\n\"Dual PI3K/Erk Inhibitor AEZS-136, A Potent Anti-Tumor Compound\n Under Preclinical Development \", M. Gerlach, I. Seipelt, L. Blumenstein, K. Jung, T. Schuster, G.\n Mueller, E. Guenther, J. Engel and M. Teifel. \n\n\n \n\n\n \n\n\n \n\n\nSession:\n\n\n \n\n\nGeneral poster session / division of medicinal chemistry;\n\n\nDates and time:\n\n \n\n\nSunday, August 19, 2012 from 7pm to 9pm (Eastern); andMonday, August 20, 2012 from 8pm to 10pm (Eastern);\n\n\nVenue:\n\n\n \n\n\nPennsylvania Convention Center, Hall D\n\n\n\n\n\nAbout AEZS-136\n\n\nAEZS-136 is an integral part of the Company's kinase research program\n comprising the investigation of different compounds for single Erk\n inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition.\n AEZS-136 selectively inhibits the kinase activity of Erk 1/2 and class\n 1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the\n PI3K-Akt signaling cascades. AEZS-136 was discovered using the\n Company's proprietary compound library and high throughput screening\n technology.\n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n company currently investigating treatments for various unmet medical\n needs. The Company's pipeline encompasses compounds at all stages of\n development, from drug discovery through to marketed products. For more\n information please visit www.aezsinc.com.\n\n \n\n\n \n\nSOURCE: AETERNA ZENTARIS INC.\n\n\n Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. [email protected] Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. [email protected] \n","length":3063,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.